Evotec has given a thumb's up on its Phase II data on its insomnia drug EVT 201. In the trial of 149 patients over the age of 65 researchers found that the lower dose extended sleep time by nine percent while the higher dose led to a 17 percent increase in sleep time.
- see this release on the trial
Related Articles:
Insomnia market attracts drug developers. Report
PerkinElmer acquires Evotec Tech in cash buyout. Report
Evotec adds drugs in Renovis buyout. Report
Evotec shutters Alzheimer's development program. Report
Read more on: Evotech | Insomnia